[1]刘跃平,徐含青,李 明,等.TPMT遗传多态性在硫嘌呤类药物个体化治疗中的意义[J].现代检验医学杂志,2017,32(03):1-5,10.[doi:10.3969/j.issn.1671-7414.2017.03.001]
 LIU Yue-ping,XU Han-qing,LI Ming,et al.Role of TPMT Genetic Polymorphism in the Individualized Treatment of Thiopurine Drug[J].Journal of Modern Laboratory Medicine,2017,32(03):1-5,10.[doi:10.3969/j.issn.1671-7414.2017.03.001]
点击复制

TPMT遗传多态性在硫嘌呤类药物个体化治疗中的意义()
分享到:

《现代检验医学杂志》[ISSN:/CN:]

卷:
第32卷
期数:
2017年03期
页码:
1-5,10
栏目:
述评
出版日期:
2017-05-25

文章信息/Info

Title:
Role of TPMT Genetic Polymorphism in the Individualized Treatment of Thiopurine Drug
文章编号:
1671-741 4(2017)03-001-06
作者:
刘跃平12徐含青1李 明2黄 庆1府伟 灵1
1.第三军医大学第一附属医院检验科,重庆 400038;
2.解放军第四七七医院检验科,湖北襄阳 441004
Author(s):
LIU Yue-ping12XU Han-qing1LI Ming1H UANG Qing2FU Wei-ling2
1.Department of Laboratory Medicine,the First Affiliated Hospi tal of the Third Military Medical University,Chongqing,400038,China;
2.Dep artment of Laboratory Medicine,477th Hospital of PLA,Hubei Xiangyang,441004,Ch ina
关键词:
巯基嘌呤甲基转移酶硫嘌呤类药物个体化用药单核苷多 态性
分类号:
R969;R446.112
DOI:
10.3969/j.issn.1671-7414.2017.03.001
文献标志码:
A
摘要:
巯基嘌呤甲基转移酶(thiopurine s-methyltransferase, TPMT)是硫嘌呤类药物在体内代谢的关键酶,其活性的高低可直接影响该类药物的临床疗效 和毒性程度。鉴于此,该文主要从“用药前是否需要检测TPMT活性、是检测基因型还是检测 表型以及TPMT基因型检测方法的选择”三个比较受关注的方面作一综述,旨在提高对TPMT 遗传多态性在硫嘌呤类药物个体化治疗中的意义的认识。
Abstract:
Thiopurine S-methyltransferase (TPMT) is an imp ortant and key cytoplasmic enzyme in the metabolism of thiopurine drugs,whose a ctivity can directly determine the amount of thiopurine drugs metabolized to cyt otoxic 6-thioguanine nucleotides and consequently influence clinical efficacy a nd adverse drug reactions of thiopurine drugs.In order to deepen knowledge and role of genetic polymorphism of tpmt in the individualized thiopurine drug treat ment,this present review mainly covered the following three frequently concerne d aspects,including i) whether or not to determine the activity of TPMT priot t o treatment of thiopurine drugs;ii) to genotype or to phenotype;iii) how to ch oose genotype methods.

参考文献/References:

[1] Schwab M,Schaffeler E,Marx C,et al.Azathioprine therapy and a dverse drug reactions in patients with inflammatory bowel disease:impact of thi opurine S-methyltransferase polymorphism[J].Pharmacogenetics,2002,12(6):4 29-436.
[2] Jun JB,Cho DY,Kang C,et al.Thiopurine S-methyltransferase polymorphi sms and the relationship between the mutant alleles and the adverse effects in s ystemic lupus erythematosus patients taking azathioprine[J].Clin Exp Rheumato l,2005,23(6):873-876.
[3] Lennard L.TPMT in the treatment of Crohn’s disease with azathioprine[J ].Gut,2002,51(2):143-146.
[4] Costantino G,Furfaro F,Belvedere A,et al.Thiopurine treatment in infl ammatory bowel disease:response predictors,safety,and withdrawal in follow-u p[J].J Crohns Colitis,2012,6(5):588-596.
[5] Van Dieren JM,Hansen BE,Kuipers EJ,et al.Meta-analysis inosine triph osphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment o f inflammatory bowel disease[J].Aliment Pharmacol Ther,2007,26(5):643-652 .
[6] Roberts RL,Barclay ML.Update on thiopurine pharmacogenetics in inflamm atory bowel disease[J].Pharmacogenomics,2015,16(8):891-893.
[7] 府伟灵,黄 庆.分子诊断与个体化医疗[J].临床检验杂志,2012,30(10):74 6-748. Fu WL,Huang Q.Molecular diagnosis and individualized medicine[J] .Chin J Clin Lab Sci,2012,30(10):746-748.
[8] 周宏灏,王连生.个体化药物治疗及其基因诊断[J].中华检验医学杂志,2005, 28(12):1227-1229. Zhou HH,Wang LS.Personalised medical treatments and gene diagnosis [J].Chin J Lab Med,2005,28(12):1227-1229.
[9] Woodson LC,Weinshilboum RM.Human kidney thi-opurine methyltransferase. Purification and biochemical properties[J].Biochem Pharmacol,1983,32(5):8 19-826.
[10] Szumlanski C,Otterness D,Her C,et al.Thiopurine methyltransf erase pharmacogenetics:human gene cloning and characterization of a common poly morphism[J].DNA Cell Biol,1996,15(1):17-30.
[11] Weinshilboum RM,Raymond FA,Pazmino PA.Human erythrocyte thiopurine me thyltransferase:radiochemical microassay and biochemical properties[J].Clin Chim Acta,1978,85(3):323-333.
[12] Appell ML,Berg J,Duley J,et al.Nomenclature for alleles of the thiop urine methyltransferase gene[J].Pharmacogenetics and Genomics,2013,23(4):2 42-248.
[13] Krynetski EY,Schuetz JD,Galpin AJ,et al.A single point mutation lead ing to loss of catalytic activity in human thiopurine S-methyltransferase[J] .Proc Natl Acad Sci USA,1995,92(4):949-953.
[14] Wang L,Pelleymounter L,Weinshilboum R,et al.Very important pharmacog ene summary:thiopurine S-methyltransferase[J].Pharmacogenet Genomics,2010 ,20(6):401-405.
[15] Otterness D,Szumlanski C,Lennard L,et al.Human thiopurine methyltran sferase pharmacogenetics:gene sequence polymorphisms[J].Clin Pharmacol Ther ,1997,62(1):60-73.
[16] Schaeffeler E,Fischer C,Brockmeier D,et al.Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large popu lation of German-Caucasians and identification of novel TPMT variants[J].Pha rmacogenetics,2004,14(14):407-417.
[17] Lennard L.Implementation of TPMT testing[J].Br J Clin Pharmacol,201 4,77(4):704-714.
[18] Hon YY,Fessing MY,Pui CH,et al.Polymorphism of the thiopurine S-met hyltransferase gene in African-Americans[J].Hum Mol Genet,1999,8(2):371- 376.
[19] 单婷婷,董瑞华,秦小清,等.药物基因多态性与个体化用药的研究进展[J]. 医药导报,2010,29(1):64-67. Shan TT,Dong RH,Qin XQ,et al.Genetic polymorphisms of drugs and indivi dualized medicine:Progresses of development[J].Herald of Medicin,2010,29(1 ):64-67.
[20] Donnan JR,Ungar WJ,Mathews M,et al.Systematic review of thiopurine m ethyltransferase genotype and enzymatic testing strategies[J].Ther Drug Monit ,2011,33(2):192-199.
[21] Roy LM,Zur RM,Uleryk E,et al.Thiopurine sme-thyltransferase testing for averting drug toxicity in patients receiving thiopurines:a systematic revi ew[J].Pharmacogenomics,2016,17(6):633-656.
[22] Zhang LR,Song DK,Zhang W,et al.Efficient sc-reening method of the t hiopurine methyltransferase polymorphisms for patients considering taking thiopu rine drugs in a Chinese Han population in Henan Province(central China)[J].Cl in Chim Acta,2007,376(1/2):45-51.
[23] Yates CR,Krynetski EY,Loennechen T,et al.Molecular diagnosis of thio purine S-methyltransferase deficiency:genetic basis for azathioprine and merca ptopurine intolerance[J].Ann Intern Med,1997,126(8):608-614.
[24] Wittwer CT.High-resolution DNA melting analysis:advancements and limi tations[J].Hum Mutat,2009,30(6):857-859.
[25] Xin HW,Xiong H,Wu XC,et al.Relationships between thiopurine S-methy ltransferase polymorphism and azathioprine-related adverse drug reactions in Ch inese renal transplant recipients[J].Eur J Clin Pharmacol,2009,65(3):249- 255.
[26] Spire-Vayron de la Moureyre C,Debuysere H,Sabbagh N,et al.Detection of known and new mutations in the thiopurine S-methyltransferase gene by singl e-strand conformation polymorphism analysis[J].Hum Mutat,1998,12(3):177- 185.
[27] 冯 静,王雪丁,李 萌,等.影响硫嘌呤类药物个体化应用的主要代谢酶遗传多 态性的研究进展[J].中国药师,2015,18(2):296-300. Feng J,Wang XD,Li M,et al.Progress in genetic polymorphism of related metabolic enzymes influencing individualized thiopurine therapy[J].China Phar macist,2015,18(2):296-300.
[28] Zabala W,Cruz R,Barreiro-de Acosta M,et al.New genetic associations in thiopurine-related bone marrow toxicity among inflammatory bowel disease pa tients[J].Pharmacogenomics,2013,14(6):631-640.
[29] Heap GA,Weedon MN,Bewshea CM,et al.HLA-DQA1-HLA-DRB1 variants co nfer susceptibility to pancreatitis induced by thiopurine immunosuppressants[J ].Nat Genet,2014,46(10):1131-1134.
[30] 王芳芳,尤崇革,李光迪,等.PCR-HRM技术在华法林最佳用药剂量关联基因单核 苷酸多态性检测中的应用[J].现代检验医学杂志,2011,26(2):32-34. Wang FF,You CG,Li GD,et al.A Rapid PCR-HRM genotyping technique for t he single nucleotide polymorphisms of genes that influence response to warfarin dose[J].Journal of Modern Laboratory Medicine,2011,26(2):32-34.
[31] 陈 蕾,刘志忠,贾淑芬,等.双管单色荧光PCR法与基因芯片法检测CYP2C19基因 多态性的比较研究[J].现代检验医学杂志,2016,31(4):51-53,57. Chen L,Liu ZZ,Jia SF,et al.Comparing study of double tube and one-col or fluorescent PCR technology and gene chip method in detecting the CYP2C19 gene polymorphisms[J].Journal of Modern Laboratory Medicine,2016,31(4):51-53 ,57.

备注/Memo

备注/Memo:
基金项目: 本课题受到国家自然科学基金面上项目(No.31370853)资助。
作者简介:刘跃平(1984-),男,硕士学历, 主管技师,主要研究方向为生化设备的性能评价及个体化用药的实验室诊断,E-mail:liu -0214@163.com。 徐含青(1985-),女,硕士学历,技 师,初级职称,主要研究方向为生化设备的性能评价及分子生物学,E-mail:22554227@q q.com。共同第一作者。
更新日期/Last Update: 2017-06-25